Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2026

Comparative Evaluation of 1,8 cineole on inhibition and migration of Human Ovarian Cancer Cell Lines SKOV3 and PA-1

View Full Paper
Ask AI
Bookmark
Share

Authors

SJSaloni JoshiRBRuby BeniwalRGReema Gabrani

Discussion

Loading...

Member takes

Overview

Comparative evaluation reveals 1,8 cineole inhibits growth and migration in ovarian cancer cell lines, suggesting therapeutic potential.

Key Points

  • The study aims to evaluate the effects of 1,8 cineole on ovarian cancer cell lines SKOV3 and PA-1, focusing on cell growth and migration.
  • In vitro cell viability assays were conducted to measure the anti-cancer activity of 1,8 cineole.
  • Cell migration-based assays assessed changes in cellular behavior post-treatment.
  • The comparison was made between two ovarian cancer cell lines: SKOV3 and PA-1.
  • 1,8 cineole significantly reduced growth in SKOV3 and PA-1 cell lines.
  • A notable decrease in migratory potential of both cell lines was observed upon exposure to 1,8 cineole, indicating its interference in cancer progression processes.

Cite This Study

Joshi et al. (2026) studied this question.

synapsesocial.com/papers/69edac2e4a46254e215b4016https://doi.org/10.1051/bioconf/202623301001/pdf
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A study of the anticancer effect of 1,8 cineole: Molecular docking analysis2024 · 2 citations
  2. 21,8-cineole as a multi-target anticancer candidate integrating molecular mechanisms, pharmacokinetics and translational perspectives.2026
  3. 3Corylin Exhibits Anticancer Activity by Inducing Apoptosis and G0/G1 Cell Cycle Arrest in SKOV3 Human Ovarian Cancer Cells2025
  4. 4Biochemical and Comparative Proteomic Analyses Delineate the Anti‐Ovarian Carcinogenic Roles of Modified Calycosin2026 · 1 citations
  5. 5Abstract 7103: Evaluation of anti-parasitic agents as potential therapeutics in ovarian cancer2026